Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.5 USD | +1.86% | +2.86% | +74.82% |
May. 23 | U.S. FDA advisers back approval for Guardant's cancer test | RE |
May. 14 | Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.82% | 13.45B | |
+17.74% | 83.47B | |
-29.66% | 69.72B | |
0.00% | 26.5B | |
+3.06% | 17.69B | |
-12.16% | 16.83B | |
+2.47% | 15.7B | |
+73.52% | 12.81B | |
+0.76% | 12.69B | |
+2.74% | 12.42B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- Earnings Flash (NTRA) NATERA Reports Q1 Revenue $367.7M, vs. Street Est of $315.3M